Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
J Endocrinol Invest ; 30(1): 65-9, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17318025

RESUMEN

A benign virilizing adrenal adenoma is rare among adrenal neoplasms in middle-aged women. A 39-yr-old Japanese woman who presented with hirsutism, obesity, diabetes mellitus and hypertension was admitted. Plasma concentrations of testosterone and DHEAS were high. While the basal level of plasma ACTH was suppressed, serum cortisol level was high and its circadian rhythm was absent. Serum cortisol level was not suppressed with the low- and high-dose overnight dexamethasone suppression test. Abdominal computed tomography showed a left adrenal tumor, and an adrenocortical scintigraphy revealed uptake of the tracer on the left side. Polycystic ovaries were also found and bone mineral density revealed osteoporosis. Histopathological features of resected adrenal tumor were consistent with those of adrenocortical adenoma. Immunoreactivity of all the steroidogenic enzymes was apparent in the tumor cells and particularly dehydroepiandrosterone sulfotransferase (DHEA-ST) immunoreactivity was markedly expressed. Cortical atrophy and reduced expression of DHEA-ST were detected in the cortex of the adjacent non-neoplastic adrenal gland. Plasma testosterone, DHEAS and cortisol levels returned to normal after surgery, concomitantly with the disappearance of polycystic ovaries. This is a very rare case of virilizing adrenocortical adenoma complicated with Cushing's syndrome (CS).


Asunto(s)
Neoplasias de la Corteza Suprarrenal/complicaciones , Adrenalectomía , Adenoma Corticosuprarrenal/complicaciones , Síndrome de Cushing/complicaciones , Resistencia a la Insulina , Síndrome del Ovario Poliquístico/terapia , Virilismo/terapia , Neoplasias de la Corteza Suprarrenal/diagnóstico , Neoplasias de la Corteza Suprarrenal/patología , Neoplasias de la Corteza Suprarrenal/cirugía , Adenoma Corticosuprarrenal/diagnóstico , Adenoma Corticosuprarrenal/patología , Adenoma Corticosuprarrenal/cirugía , Adulto , Femenino , Humanos , Síndrome del Ovario Poliquístico/etiología , Radiografía Abdominal , Virilismo/etiología
2.
Jpn J Cancer Res ; 92(12): 1322-8, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11749698

RESUMEN

The flavonoid nobiletin (5,6,7,8,3',4'-hexamethoxyflavone), found in Citrus depressa Rutaceae, a popular citrus fruit in Okinawa, Japan, reportedly inhibits the production of pro-matrix metalloproteinase (proMMP)-1, 3, and 9 in rabbit synovial fibroblasts in vitro. In the present study, we demonstrated the inhibitory effects of nobiletin on the proliferation of the cancer cell line, TMK- 1, and its production of MMPs. In the SCID mouse model, we found that nobiletin inhibited the formation of peritoneal dissemination nodules from TMK-1. The enzymatic activity of MMP-9 expressed in culture medium obtained from a co-culture of TMK-1 and mouse fibroblastic cells was inhibited by nobiletin in a concentration-dependent manner. In the SCID mouse model, total weight of dissemination nodules was significantly lower in the treated group compared with the vehicle control group (0.07 g vs. 0.78 g, P = 0.0059). The total number of dissemination nodules was also significantly lower than in the vehicle control group (7.5 vs. 69.3 / body, P = 0.0001). These results suggest that nobiletin may be a candidate anti-metastatic drug for prevention of peritoneal dissemination of gastric cancer.


Asunto(s)
Citrus/química , Flavonas , Flavonoides/uso terapéutico , Neoplasias Peritoneales/tratamiento farmacológico , Neoplasias Peritoneales/secundario , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/patología , Animales , Peso Corporal/efectos de los fármacos , División Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Flavonoides/química , Flavonoides/farmacología , Humanos , Metaloproteinasas de la Matriz/metabolismo , Ratones , Ratones SCID , Trasplante de Neoplasias , Tamaño de los Órganos/efectos de los fármacos , Especificidad de Órganos , Neoplasias Peritoneales/patología , Neoplasias Gástricas/enzimología , Células Tumorales Cultivadas
3.
Chemosphere ; 44(4): 743-9, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11482664

RESUMEN

Water-soluble arsenic compound fractions were extracted from seven species of jellyfishes and subjected to analysis by high-performance liquid chromatography-inductively coupled plasma mass spectrometry (HPLC-ICP-MS) for arsenicals. A low content of arsenic was found to be the characteristic of jellyfish. Arsenobetaine (AB) was the major arsenic compound without exception in the tissues of the jellyfish species and mucus-blobs collected from some of them. Although the arsenic content in Beroe cucumis, which preys on Bolinopsis mikado, was more than 13 times that in B. mikado, the chromatograms of these two species were similar in the distribution pattern of arsenicals. The nine species of jellyfishes including two species treated in the previous paper can be classified into arsenocholine (AC)-rich and AC-poor species. Jellyfishes belonging to Semaostamae were classified as AC-rich species.


Asunto(s)
Arsenicales/farmacocinética , Escifozoos/química , Contaminantes Químicos del Agua/farmacocinética , Animales , Arsenicales/análisis , Cromatografía Líquida de Alta Presión , Cadena Alimentaria , Espectrometría de Masas , Moco/química , Distribución Tisular , Contaminantes Químicos del Agua/análisis
4.
Gan To Kagaku Ryoho ; 27(7): 993-1002, 2000 Jul.
Artículo en Japonés | MEDLINE | ID: mdl-10925684

RESUMEN

This prospective randomized study aimed at establishing the optimal postoperative adjuvant chemotherapy regimen for premenopausal n+ breast cancer patients. The treatments were Regimen A, comprising 6 courses of CMF (cyclophosphamide, 100 mg/body on days 1-14; methotrexate, 40 mg/m2 on days 1 and 8; and 5-fluorouracil, 500 mg/m2 on days 1 and 8), and Regimen B, consisting of UFT (300 mg/day) and tamoxifen (30 mg/day) administered orally each day for 2 years. Telephone registration allocated the patients to the treatment groups by the minimization method in relation to the T category, number of n+ lesions and estrogen receptor status. Forty-five patients were registered, and 44 of them were eligible (22 cases each to Regimen A and Regimen B). The principal background factors showed no biases between the groups. The adverse reaction incidence was significantly higher with Regimen A (90.9% vs 22.7%). The 5-year survival rate was 89.8% with Regimen A and 100% with Regimen B, while the 5-year disease-free rates were 64.5% and 76.3%, showing no statistical significance. Regimen B showed a better QOL rating after 6 months of therapy in relation to nausea-vomiting and hair loss, and after 24 months in relation to appetite, sleep, performance status, happiness, anorexia and hair loss.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Adulto , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Esquema de Medicación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Metástasis Linfática , Metotrexato/administración & dosificación , Persona de Mediana Edad , Estudios Prospectivos , Calidad de Vida , Tasa de Supervivencia , Tamoxifeno/administración & dosificación , Tegafur/administración & dosificación , Uracilo/administración & dosificación
5.
J Trauma ; 42(2): 183-90, 1997 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9042868

RESUMEN

Branched chain amino acids (BCAAs) and glutamine are both recommended in catabolic states. The object of this study was to compare the efficacies of alanylglutamine (Ala-Gln)-enriched and BCAA-enriched total parenteral nutrition (TPN) on the protein kinetics in peritonitis. Rats were divided into Ala-Gln and BCAA groups after intraperitoneal implantation of an osmotic pump, delivering a continuous infusion of Escherichia coli. Glutamine composed 30.0% (w/v) of the total amino acids in the Ala-Gln group, and BCAA composed 30.5% (w/v) of the total amino acids in the BCAA group. The two solutions were isocaloric and isonitrogenous. Whole body protein turnover and organ fractional protein synthetic rates (FSR) were measured on days 3 and 5. Serum amino acid levels and mucosal morphology were determined. Ala-Gln group had higher rates of whole body protein turnover, and hepatic FSR on both days. Serum glutamine levels correlated with hepatic and muscle FSR. Ala-Gln TPN group had greater mucosal thickness, numbers of mitoses per crypt, and FSR in distal intestine. Ala-Gln-enriched TPN may be a useful nutritional treatment modality in sepsis.


Asunto(s)
Aminoácidos de Cadena Ramificada/uso terapéutico , Dipéptidos/uso terapéutico , Nutrición Parenteral Total/métodos , Peritonitis/metabolismo , Peritonitis/terapia , Proteínas/metabolismo , Aminoácidos/sangre , Animales , Modelos Animales de Enfermedad , Masculino , Peritonitis/sangre , Ratas , Ratas Wistar
6.
JPEN J Parenter Enteral Nutr ; 20(6): 417-23, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8950743

RESUMEN

BACKGROUND: The effects of glutamine-enriched total parenteral nutrition (TPN) solution on survival, and protein turnover in the whole body and in individual organs were investigated in a rat protracted peritonitis model. METHODS: Twenty-three rats underwent venous catheter insertion. Osmotic pumps were implanted in the peritoneal cavity to allow continuous delivery of Escherichia coli (4 x 10(8) CFU/d). The conventional TPN group received a conventional amino acid solution. The Ala-Gln TPN group received an alanyl-glutamine-enriched TPN solution. The two TPN solutions were isocaloric and isonitrogenous. RESULTS: Over the 5 days of TPN treatment, the survival rate of the Ala-Gln group was significantly higher than that of the conventional group. The Ala-Gln group tended to have increased whole-body protein turnover compared with the conventional group. Fractional protein synthetic rates (FSR) in the liver and gastrocnemius muscle of the Ala-Gln group were significantly higher than those of the conventional group. The serum glutamine concentration correlated positively with the FSR of both liver and muscle. The Ala-Gln group showed significantly greater mucosal height and mitoses per crypt, in the small intestine, than did the conventional group. CONCLUSIONS: Our results suggested that, in comparison with standard glutamine-free TPN, Ala-Gln-supplemented TPN increases protein synthesis in the liver and skeletal muscle, protects the morphology of the intestinal mucosa, and improves survival in protracted bacterial peritonitis. Ala-Gln supplementation may be useful in septic patients.


Asunto(s)
Alanina/administración & dosificación , Infecciones por Escherichia coli , Glutamina/administración & dosificación , Nutrición Parenteral Total , Peritonitis/terapia , Proteínas/metabolismo , Aminoácidos/sangre , Animales , Infecciones por Escherichia coli/metabolismo , Infecciones por Escherichia coli/terapia , Intestino Delgado/patología , Masculino , Peritonitis/microbiología , Peritonitis/mortalidad , Biosíntesis de Proteínas , Ratas , Ratas Wistar , Tasa de Supervivencia
7.
Biochemistry ; 31(12): 3051-8, 1992 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-1554693

RESUMEN

Human germ cell alkaline phosphatase (GCAP), which shares 98% amino acid sequence identity with the placental AP (PLAP), is expressed by malignant trophoblasts. Protein sequence analysis suggests that the Ser residue at position 92 is the putative active site of GCAP which contains two recognition sequences (Asn122-Thr-Thr124 and Asn249-Arg-Thr251) for asparagine-linked glycosylation. To examine the roles of the Ser residue and glycan moieties on GCAP activity and processing, we altered the GCAP cDNA by site-directed mutagenesis and expressed the GCAP mutants in COS-1 cells. Substitution of Ser-92 with either a Thr (S92T) or an Ala (S92A) residue yielded a GCAP devoid of catalytic activity, suggesting that the Ser codon 92 is the active site of GCAP. Six GCAP mutants that lack one or both glycosylation sites were constructed by substituting either Asn-122 or Asn-249 with an Asp residue or either Thr-124 or Thr-251 with an Ala residue. The mature GCAP migrated as a 65-kDa product, but GCAP mutants lacking one or both glycosylation sites migrated as 62- or 58-kDa polypeptides, respectively, indicating that both sites were glycosylated. All six glycosylated mutants were active enzymatically and, in addition, were equally sensitive to heat, L-leucine, and EDTA inhibition as the parental enzyme. GCAP as well as its two active-site and six glycosylation mutants could be released from the plasma membrane of transfected COS-1 cells by the proteinase bromelain.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Fosfatasa Alcalina/química , Isoenzimas/química , Mutagénesis Sitio-Dirigida , Fosfatasa Alcalina/biosíntesis , Fosfatasa Alcalina/genética , Animales , Secuencia de Bases , Sitios de Unión , Línea Celular , Chlorocebus aethiops , Células Germinativas/química , Células Germinativas/enzimología , Glicosilación , Humanos , Isoenzimas/biosíntesis , Isoenzimas/genética , Riñón , Cinética , Proteínas de la Membrana/química , Proteínas de la Membrana/genética , Datos de Secuencia Molecular , Serina/química , Relación Estructura-Actividad
8.
Infect Immun ; 29(2): 545-50, 1980 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-7216424

RESUMEN

Human colostral specimens were obtained from 60 Japanese postpartum women within the first 3 days after delivery. Neutralizing activity against Clostridium difficile toxin was evaluated with Y1 adrenal cells in miniculture. When Y1 adrenal cells were exposed briefly to the toxin, they showed a rounding response in culture, resembling that effected by Escherichia coli enterotoxin; however, preincubation of the toxin with aqueous phase of colostrum significantly reduced its cytopathic effect on Y1 adrenal cells. Of 60 colostral specimens, 17 samples had neutralizing activity against the toxin. Cell-free supernatants of colostral cells cultured for 7 days without mitogens contained significant amounts of both immunoglobulin A (IgA) and IgM, but very small amounts of IgG. Neutralizing activity of cell-free supernatants of cultured colostral cells was evaluated as described above. Neutralizing activity against the toxin was identified in five samples of culture supernatants out of 60 colostral cell specimens. In all five cases, the aqueous phase of colostrum also had a neutralizing effect against C. difficile toxin. Neutralizing activity against the toxin found in five supernatants of cultured colostral cells was completely abolished only by anti-human IgA antibody as assessed by immune precipitation.


Asunto(s)
Clostridium/inmunología , Calostro/inmunología , Inmunoglobulina A/análisis , Células Cultivadas , Calostro/citología , Femenino , Humanos , Macrófagos/inmunología , Pruebas de Neutralización , Pruebas de Precipitina , Toxinas Biológicas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA